IL314062A - Deuterium-enriched piperidinyl-methylpurine amine compounds and related compounds and their use in the treatment of diseases and medical conditions - Google Patents

Deuterium-enriched piperidinyl-methylpurine amine compounds and related compounds and their use in the treatment of diseases and medical conditions

Info

Publication number
IL314062A
IL314062A IL314062A IL31406224A IL314062A IL 314062 A IL314062 A IL 314062A IL 314062 A IL314062 A IL 314062A IL 31406224 A IL31406224 A IL 31406224A IL 314062 A IL314062 A IL 314062A
Authority
IL
Israel
Prior art keywords
deuterium
purine
piperidinyl
enriched
amines
Prior art date
Application number
IL314062A
Other languages
English (en)
Hebrew (he)
Inventor
Terrence Joseph Connolly
Chad Arthur Lewis
Original Assignee
K36 Therapeutics Inc
Terrence Joseph Connolly
Chad Arthur Lewis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by K36 Therapeutics Inc, Terrence Joseph Connolly, Chad Arthur Lewis filed Critical K36 Therapeutics Inc
Publication of IL314062A publication Critical patent/IL314062A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL314062A 2022-01-05 2023-01-05 Deuterium-enriched piperidinyl-methylpurine amine compounds and related compounds and their use in the treatment of diseases and medical conditions IL314062A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263296676P 2022-01-05 2022-01-05
PCT/US2023/010204 WO2023133201A1 (en) 2022-01-05 2023-01-05 Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions

Publications (1)

Publication Number Publication Date
IL314062A true IL314062A (en) 2024-09-01

Family

ID=87074217

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314062A IL314062A (en) 2022-01-05 2023-01-05 Deuterium-enriched piperidinyl-methylpurine amine compounds and related compounds and their use in the treatment of diseases and medical conditions

Country Status (10)

Country Link
US (2) US12492203B2 (enExample)
EP (1) EP4460502A4 (enExample)
JP (1) JP2025504379A (enExample)
KR (1) KR20240158230A (enExample)
CN (1) CN119032094A (enExample)
AU (1) AU2023205553A1 (enExample)
CA (1) CA3242612A1 (enExample)
IL (1) IL314062A (enExample)
MX (1) MX2024008450A (enExample)
WO (1) WO2023133201A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021026803A1 (en) 2019-08-14 2021-02-18 Novartis Ag Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
CN120641105A (zh) * 2022-12-12 2025-09-12 K36治疗股份有限公司 含有哌啶基甲基嘌呤胺的药物组合物及其在治疗疾病和疾患中的用途
AU2024381513A1 (en) * 2023-11-17 2026-06-04 K36 Therapeutics, Inc. Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
CN117843641B (zh) * 2023-12-28 2025-04-25 和径医药科技（上海）有限公司 Nsd3抑制剂及其制备方法和应用
WO2025259850A1 (en) * 2024-06-12 2025-12-18 K36 Therapeutics, Inc. Pharmaceutical compositions containing a deuterium-enriched piperidinyl-methyl-purine amine and their use in treating diseases and conditions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ591615A (en) 2008-09-18 2012-07-27 Auspex Pharmaceuticals Inc Benzoquinoline inhibitors of vesicular monoamine transporter 2
EP2463289A1 (en) * 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
WO2021026803A1 (en) 2019-08-14 2021-02-18 Novartis Ag Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents
CN114981270B (zh) 2019-09-20 2024-10-18 诺华公司 Mll1抑制剂和抗癌剂
AR122159A1 (es) 2020-05-28 2022-08-17 Novartis Ag Inhibidores de mll1 y agentes antineoplásicos
US20250326752A1 (en) 2022-05-18 2025-10-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
JP2025517349A (ja) 2022-05-18 2025-06-05 ケイ３６・セラピューティクス・インコーポレイテッド ピペリジニル－メチル－プリンアミンｄ－酒石酸塩、結晶形態、ならびに医学的疾患及び状態の治療におけるそれらの使用
WO2023225144A1 (en) 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023225150A1 (en) 2022-05-18 2023-11-23 K36 Therapeutics, Inc. Piperidinyl-methyl-purine amine fumaric acid salts, crystalline forms, and their use in treating medical diseases and conditions
WO2023230038A1 (en) 2022-05-23 2023-11-30 K36 Therapeutics, Inc. Piperidinyl-methylpurine pyrimidines and related compounds and their use in treating diseases and conditions
US20250361235A1 (en) 2022-05-23 2025-11-27 K36 Therapeutics, Inc. Piperidinyl-methylpurine benzenes and related compounds and their use in treating diseases and conditions
WO2024055048A1 (en) 2022-09-09 2024-03-14 The Trustees Of Columbia University In The City Of New York Methods of treating neuroendocrine prostate cancer (nepc) by inhibiting nuclear receptor binding set domain protein 2 (nsd2)
CN120641105A (zh) 2022-12-12 2025-09-12 K36治疗股份有限公司 含有哌啶基甲基嘌呤胺的药物组合物及其在治疗疾病和疾患中的用途
AU2024381513A1 (en) 2023-11-17 2026-06-04 K36 Therapeutics, Inc. Deuterium-enriched piperidinyl-methyl-purine amine salts, crystalline forms, and their use in treating medical diseases and conditions

Also Published As

Publication number Publication date
CA3242612A1 (en) 2023-07-13
EP4460502A1 (en) 2024-11-13
US20260049083A1 (en) 2026-02-19
MX2024008450A (es) 2024-12-06
CN119032094A (zh) 2024-11-26
US20240352017A1 (en) 2024-10-24
JP2025504379A (ja) 2025-02-12
AU2023205553A1 (en) 2024-07-25
WO2023133201A1 (en) 2023-07-13
US12492203B2 (en) 2025-12-09
KR20240158230A (ko) 2024-11-04
EP4460502A4 (en) 2025-12-24

Similar Documents

Publication Publication Date Title
IL297849B1 (en) Composition for use in the treatment of APOL1-related disease
IL288574A (en) Oligonucleotides and methods for use in the treatment of neurological diseases
IL289167A (en) The history of 2h-indazole and their use in the treatment of diseases
GB202108572D0 (en) Therapeutic compounds and their use
HUE071972T2 (hu) Vegyületek és készítmények bõrrendellenességek kezelésében történõ alkalmazásra
PL4313010T3 (pl) Związki do zastosowania w leczeniu i profilaktyce covid-19
IL321370A (en) Medicinal compositions containing piperidinyl-methyl-purine amines and their use in the treatment of diseases and conditions
IL318209A (en) Medical compounds and methods
PL4419526T3 (pl) Związki heterocykliczne do stosowania w leczeniu nowotworu
IL327476A (en) Modified oligonucleotides and methods for using them
IL309878A (en) Therapeutic compounds and methods
GB202214972D0 (en) Products and methods for use in treating NDP-related diseases
IL314316A (en) Compounds and their use in cancer treatment
GB202302120D0 (en) Compounds for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction
HK40119453A (en) Deuterium-enriched piperidinyl-methyl-purine amines and related compounds and their use in treating diseases and conditions
IL313183A (en) Peptides and methods for use in treating pain
EP4193995A4 (en) USE OF BTK INHIBITORS TO TREAT DISEASES
IL326065A (en) Methods of treating medical conditions and diseases
IL319234A (en) Pyrazolylsulfonamide compounds and their use in therapy
DK3937948T3 (da) Phytoecdysoner og derivater deraf til anvendelse i behandlingen af neuromuskulære sygdomme
EP4433430A4 (en) COMPOSITION AND METHOD FOR CONDITIONING WATER IN SPAS
GB202306474D0 (en) Seed treatment composition and use
EP3907747C0 (en) TRANSFORMER AND ITS MANUFACTURING METHOD
IL272074A (en) Peptide compounds and methods of treating diseases using same
GB202305546D0 (en) Novel compounds and their use in therapy